PREVALENCE OF CLAUDIN18.2 AND PD-L1 EXPRESSION IN CHINESE GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

被引：1
|
作者：
Mao, Linlin [1 ]
Yi, Wei [1 ]
Lin, Xu-Alan [1 ]
Gu, Ying [1 ]
Xia, Zhenzhong [1 ]
Qi, Chuan [1 ]
Shi, Michael [1 ]
Yu, Steven [1 ]
Qian, Xueming [1 ]
机构：
[1] Suzhou Transcenta Therapeut Co Ltd, Suzhou, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
105
引用
收藏
页码：A115 / A115
页数：1
相关论文
共 50 条
  • [21] Pathologist reproducibility of combined positive score (CPS) for the evaluation of PD-L1 in gastric or gastroesophageal junction adenocarcinoma tumors
    Guerrero, Lindsay
    Kulangara, Karina
    Truong, Yen
    Schwefel, Sue
    Hanks, Debra
    CANCER RESEARCH, 2018, 78 (13)
  • [22] Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study
    Gong, Jifang
    Shen, Lin
    Hou, Jie
    Chen, Xiaohua
    Yu, Qin
    Zheng, Ying
    Wang, Yakun
    Zhang, Jian
    Qu, Xiangdong
    Lu, Qiying
    Du, Yejie
    Pan, Qin
    Xu, Wencheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
    Robert, Marie E.
    Ruschoff, Josef
    Jasani, Bharat
    Graham, Rondell P.
    Badve, Sunil S.
    Rodriguez-Justo, Manuel
    Kodach, Liudmila L.
    Srivastava, Amitabh
    Wang, Hanlin L.
    Tang, Laura H.
    Troncone, Giancarlo
    Rojo, Federico
    Van Treeck, Benjamin J.
    Pratt, James
    Shnitsa, Iryna
    Kumar, George
    Karasarides, Maria
    Anders, Robert A.
    MODERN PATHOLOGY, 2023, 36 (05)
  • [24] FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
    Fashoyin-Aje, Lola
    Donoghue, Martha
    Chen, Huanyu
    He, Kun
    Veeraraghavan, Janaki
    Goldberg, Kirsten B.
    Keegan, Patricia
    McKee, Amy E.
    Pazdur, Richard
    ONCOLOGIST, 2019, 24 (01): : 103 - 109
  • [25] Laparoscopic curative resection following perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel and its influence on Claudin18.2 expression in advanced gastric or gastroesophageal junction adenocarcinoma: a two-case report
    Tohru Takahashi
    Takahiro Ishii
    Taku Maejima
    Eriko Aimono
    Dai Miyazaki
    Susumu Fukahori
    Taichi Kimura
    Mitsuru Yanai
    Yusuke Ono
    Masahiro Hagiwara
    Yusuke Mizukami
    Discover Oncology, 16 (1)
  • [26] Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
    Moran, D.
    Maurus, D.
    Rohde, C.
    Arozullah, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer
    Wu, Jian
    Chen, Jun
    Zhao, Yuetong
    Yuan, Mengyun
    Chen, Xu
    He, Xiangdong
    Zhang, Jun
    Shao, Guoqiang
    Sun, Qingmin
    MOLECULAR PHARMACEUTICS, 2024, 21 (07) : 3447 - 3458
  • [28] HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches
    Freitas, Marta Baptista
    Gullo, Irene
    Leitao, Dina
    Aguas, Lucia
    Oliveira, Carla
    Polonia, Antonio
    Gomes, Joana
    Carneiro, Fatima
    Reis, Celso Albuquerque
    Duarte, Henrique Oliveira
    CANCERS, 2024, 16 (06)
  • [29] Neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy in resectable gastric and gastroesophageal junction cancer
    Taherifard, Erfan
    Saeed, Anwaar
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
  • [30] Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
    Moran, Diarmuid Martin
    Guerrero, Abraham
    Ueno, Yoko
    Park, Jung Wook
    Pavese, Janet
    Kaneko, Yuichiro
    Matsangou, Maria
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 466 - 466
12345